Recruiting Atrial Fibrillation Studies in New York
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
The purpose of this pragmatic study is to evaluate the safety, performance and effectiveness of the FARAPULSE catheter system (FARAWAVE catheter used in combination with the FARASTAR generator), to tr...
MAGIC Ruxolitinib for aGVHD
This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cel...
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem ...
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with H...
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for peopl...
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD....
SPEARHEAD-3 Pediatric Study
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....
About Atrial Fibrillation Clinical Trials in New York
Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.
There are currently 8 atrial fibrillation clinical trials recruiting participants in New York, NY. These studies are seeking a combined 1,412 participants. Research is being sponsored by Eli Lilly and Company, Vivek Reddy, John Levine and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Atrial Fibrillation Clinical Trials in New York — FAQ
Are there atrial fibrillation clinical trials in New York?
Yes, there are 8 atrial fibrillation clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New York?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.
Are clinical trials in New York free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.
What atrial fibrillation treatments are being tested?
The 8 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.
Data updated March 2, 2026 from ClinicalTrials.gov